SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today reported business progress and financial results for the third quarter ended September 30, 2016.
“We continue to make important progress across our GBT440 development programs and are particularly excited to have reached agreement with the FDA on key elements of our Phase 3 HOPE Study design for GBT440 in sickle cell disease (SCD),” said Ted W. Love, M.D., president and chief executive officer of GBT. “SCD is an urgent unmet medical need, and we believe the HOPE Study is uniquely designed to demonstrate the benefit of GBT440’s mechanism of action. We look forward to initiating clinical trial sites for this Phase 3 study and beginning to screen patients by December.”
“We continue to make important progress across our GBT440 development programs and are particularly excited to have reached agreement with the FDA on key elements of our Phase 3 HOPE Study design for GBT440 in sickle cell disease (SCD),” said Ted W. Love, M.D., president and chief executive officer of GBT. “SCD is an urgent unmet medical need, and we believe the HOPE Study is uniquely designed to demonstrate the benefit of GBT440’s mechanism of action. We look forward to initiating clinical trial sites for this Phase 3 study and beginning to screen patients by December.”
